Sandoz US to divest dermatology and oral solids businesses to Aurobindo Pharma for $1bn
In a strategic move within the pharmaceutical industry, Sandoz US, a subsidiary of the Swiss-based Novartis, has announced the sale of its dermatology and oral ... Read More
Feinstein Institute discovers potential of ACE inhibitors in preventing memory loss in lupus patients
New York-based Feinstein Institute for Medical Research finds that ACE inhibitors can prevent cognitive decline in lupus patients, according to a study published in the ... Read More
Avara Pharmaceutical expands into Canadian market with acquisition of sterile manufacturing facility
Avara Pharmaceutical Services, a prominent US-based contract development and manufacturing organization (CDMO), has successfully completed the acquisition of a sterile manufacturing facility for injectable medicines ... Read More
Compugen initiates Phase 1 trial of COM701 cancer immunotherapy in advanced solid tumors
Israeli pharmaceutical company Compugen has announced the commencement of a phase 1 clinical trial for its innovative cancer immunotherapy antibody, COM701, targeting patients with advanced ... Read More
4D Molecular Therapeutics secures $90m in Series B to advance gene therapy innovations
California-based 4D Molecular Therapeutics (4DMT), specializing in adeno-associated virus (AAV) gene therapy vector discovery and product development, has successfully raised $90 million through a Series ... Read More
Olon acquires API manufacturing plant in Maharashtra, India to expand global footprint
Olon, a prominent developer and manufacturer of active pharmaceutical ingredients (API) based in Italy, has strategically expanded its global operations with the acquisition of a ... Read More
SillaJen and Lee’s Pharmaceutical launch Phase 3 trial of Pexa-Vec in China for advanced liver cancer
In a significant development in the fight against liver cancer, South Korean biotech company SillaJen, in partnership with Hong Kong-based Lee's Pharmaceutical, has announced the ... Read More
Evox Therapeutics secures £35.5m in Series B to advance exosome therapeutics
Evox Therapeutics, an innovative biotechnology company spun out from Oxford University, has successfully raised £35.5 million in a Series B financing round. The round was ... Read More
FDA declines approval for Sunovion’s ADHD drug dasotraline, citing need for more data
In a regulatory setback, the U.S. Food and Drug Administration (FDA) has decided not to approve Sunovion Pharmaceuticals’ dasotraline, a dual-acting dopamine and norepinephrine reuptake ... Read More
Kodiak Sciences completes enrollment for KSI-301 safety study in retinal disease
Kodiak Sciences, a California-based biotechnology company, has recently completed patient enrollment for a phase 1 safety and tolerability study of its innovative retinal disease drug, ... Read More